MedTrace Logo

Saline Contrast Electrical Impedance Tomography Method for Diagnosis of Acute Pulmonary Embolism

NCT07190079 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 343

Last updated 2025-10-02

No results posted yet for this study

Summary

The goal of this observational study is to compare the consistency of saline contrast Electrical Impedance Tomography(EIT) method and Computed Tomography Pulmonary Angiography (CTPA) in diagnosing acute pulmonary embolism. The main question it aims to answer is:

Can bedside saline contrast EIT method be used for the diagnosis of acute pulmonary embolism? The participants will undergo saline contrast EIT and CTPA examinations successively within 24 hours.

Conditions

  • Acute Pulmonary Embolism

Interventions

DIAGNOSTIC_TEST

Saline contrast Electrical Impedance Tomography method

This study will enroll patients with clinically suspected or confirmed acute pulmonary embolism (PE) presenting with acute respiratory failure, who undergo electrical impedance tomography (EIT) with saline contrast within 24 hours before or after computed tomography pulmonary angiography (CTPA). The EIT procedure is performed as follows: 1. Breath-Hold Maneuver: (1)Spontaneous breathing patients: Supine position, instructed to hold expiration for ≥8 seconds. (2)Mechanically ventilated patients: Expiratory hold (\>8 sec) achieved via ventilator; deeper sedation will be applied when feasible to prolong breath-hold. 2. Venous Access: (1)Preferred: Central venous catheter (internal jugular or subclavian vein).(2)Alternative: Peripheral forearm vein (preferably the median cubital vein). 3. Contrast Administration:(1)Central venous route: 10 mL of 10% NaCl.(2)Peripheral venous route: 15 mL of 5% NaHCO₃.

DIAGNOSTIC_TEST

Computed Tomography Pulmonary Angiography (CTPA)

Patients who meet the inclusion criteria will undergo CTPA examination using conventional clinical diagnostic methods.

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-24
Primary Completion
2027-05-01
Completion
2027-09-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07190079 on ClinicalTrials.gov